Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 15, 2013 08:00 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin Announces French ATU Granted for Vimizim(TM) for the Treatment of Morquio A Syndrome

SAN RAFAEL, Calif., Nov. 15, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that the French National Agency for Medicines and Health Products Safety (ANSM) has...
November 05, 2013 08:30 ET | Source: BioMarin Pharmaceutical Inc.

Jean-Jacques Bienaime, CEO of BioMarin, to Present at the Credit Suisse 2013 Healthcare Conference

SAN RAFAEL, Calif., Nov. 5, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Jean-Jacques Bienaimé, Chief Executive Officer at BioMarin, will present a...
October 31, 2013 05:00 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin Initiates Phase 3 Trial for BMN 673 for the Treatment of Metastatic gBRCA Breast Cancer

SAN RAFAEL, Calif., Oct. 31, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that it has dosed the first patient in its Phase 3 program to evaluate BMN 673, its...
October 24, 2013 17:33 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin Announces Third Quarter 2013 Financial Results

Total Revenue Grows 6.9% in the Quarter and 8.9% for First Three Quarters of 2013 Advisory Committee Meeting for Vimizim Scheduled for November 19, 2013 Conference Call and Webcast to Be Held...
October 20, 2013 12:30 ET | Source: BioMarin Pharmaceutical Inc.

Five Data Presentations on BioMarin's BMN 673 PARP Inhibitor at the 2013 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

SAN RAFAEL, Calif., Oct. 20, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that five poster presentations on BMN 673 will be featured at the 2013 AACR-NCI-EORTC...
October 10, 2013 06:00 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin Announces Exercise by Underwriters of Full Over-Allotment Option

SAN RAFAEL, Calif., Oct. 10, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced that the underwriters for its recently announced public offering of $680 million of its...
October 10, 2013 05:00 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin to Host Third Quarter 2013 Financial Results Conference Call and Webcast on Thursday, October 24 at 5:00 p.m. ET

SAN RAFAEL, Calif., Oct. 10, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Jean-Jacques Bienaimé, Chief Executive Officer of BioMarin, will host a...
October 09, 2013 06:00 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin Announces Pricing of $340 Million of Senior Subordinated Convertible Notes Due 2018 and $340 Million of Senior Subordinated Convertible Notes Due 2020

SAN RAFAEL, Calif., Oct. 9, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced the pricing on October 8, 2013 of a total offering of $680 million of its senior subordinated...
October 07, 2013 16:50 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin Announces Proposed Offering of $300 Million of Senior Subordinated Convertible Notes Due 2018 and $300 Million Senior Subordinated Convertible Notes Due 2020

SAN RAFAEL, Calif., Oct. 7, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today an offering, subject to market and other conditions, of $600 million of its senior...
September 29, 2013 04:45 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin Provides Updated Phase 1/2 Data on BMN 673 in Breast Cancer at the European Cancer Congress 2013

- Confirmed RECIST Response Rate of 50% in gBRCA Breast Cancer Patients Treated With 1mg/day Phase 3 Dose - Overall Benefit Response Rate With 1mg/day Phase 3 Dose of 86% SAN RAFAEL,...